Etilefrine

It is a sympathomimetic amine of the 3-hydroxy-phenylethanolamine series used in treating orthostatic hypotension of neurological, cardiovascular, endocrine or metabolic origin. Intravenous infusion of this compound increases cardiac output, stroke volume, venous return and blood pressure in man and experimental animals, suggesting stimulation of both α and β adrenergic receptors. However, in vitro studies indicate that etilefrine has a much higher affinity for β₁ (cardiac) than for β₂ adrenoreceptors.

Etilefrine

Clinical data
Other names	(2-ethylamino-1-(3'-hydroxy-phenyl)ethanol
AHFS/Drugs.com	International Drug Names
ATC code	C01CA01 (WHO)
Identifiers
IUPAC name (RS)-3-[2-(ethylamino)-1-hydroxyethyl]phenol
CAS Number	709-55-7
PubChem CID	3306
DrugBank	DB08985 Y
ChemSpider	3190 Y
UNII	ZB6F8MY53V
KEGG	D07931 Y
ChEMBL	ChEMBL86882 Y
CompTox Dashboard (EPA)	DTXSID1023029
ECHA InfoCard	100.010.829
Chemical and physical data
Formula	C10H15NO2
Molar mass	181.235 g·mol−1
3D model (JSmol)	Interactive image
Chirality	Racemic mixture
SMILES CCNCC(O)c1cc(O)ccc1
InChI InChI=1S/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3 Y Key:SQVIAVUSQAWMKL-UHFFFAOYSA-N Y
(verify)

Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central venous pressure and mean arterial pressure of healthy individuals. Peripheral vascular resistance falls during the infusion of 1–8 mg etilefrine but begins to rise at higher dosage. Marked falls in pulse rate, cardiac output, stroke volume and peripheral bloodflow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2,5 mg. These findings indicate that etilefrine has both β₁ and α₁ adrenergic effects in man.